15 March 2017 - The Department of Health has asked NICE to produce guidance on the use of adalimumab and dexamethasone in the NHS in England by patients with non-infectious uveitis.

Adalimumab is recommended as an option for treating non-infectious uveitis in the posterior segment of the eye in adults with inadequate response to corticosteroids, only if there is:

• active disease, that is, current inflammation in the eye
  
• macular oedema
  
• inadequate response to immunosuppressants
  
• systemic disease or both eyes are affected and
  
• worsening vision with a risk of blindness
  

Dexamethasone intravitreal implant is recommended as an option for treating non-infectious uveitis in the posterior segment of the eye in adults, only if there is:

• active disease, that is, current inflammation in the eye and
  
• macular oedema
  

Read NICE Appraisal Consultation Document for adalimumab and dexamethasone